advertisement
Rodríguez-Agirretxe I 10
Showing records 1 to 10 | Display all abstracts from Rodríguez-Agirretxe I98618 Validation of the SITA faster strategy for the management of glaucoma
Rodríguez-Agirretxe I
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Garcia-Medina JJ
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Loizate E
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Benitez-del-Castillo J
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Astorkiza B
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Rodríguez-Agirretxe I; Lopez-Lopez F
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Onaindia A; Galdos-Olasagasti L
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Moreno-Valladares A
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
98618 Validation of the SITA faster strategy for the management of glaucoma
Basasoro A
International Ophthalmology 2022; 42: 2347-2354
98993 Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 252-260
